Cardio-Phoenix

Company profile

About Cardio-Phoenix

Cardio-Phoenix has developed Cardio-HART, a clinically validated AI-powered cardiac diagnostic system that transforms point-of-care cardiac assessment in primary care. The system builds on standard 12-lead ECG functionality by adding structural and functional cardiac insights traditionally only available through echocardiography in secondary care settings. Cardio-HART uses synchronized electrical, acoustic, and mechanical biosignal sensing combined with AI models to detect electrical abnormalities, structural heart disease, valvular pathology (aortic stenosis, mitral regurgitation), and all three heart failure phenotypes (HFpEF, HFmrEF, HFrEF) during a single 10-minute examination. The system provides quantified left ventricular ejection fraction (LVEF) with severity grading, achieving over 90% agreement with echocardiographic measurements. Validated across 15,000+ patients in 14 European centers, Cardio-HART demonstrates 91.2% sensitivity and 88.6% specificity for heart failure detection, reduces inconclusive ECG results by 94%, and increases confirmed diagnoses by 160% compared to standard ECG alone. The technology enables general practitioners and primary care clinicians to make more confident referral decisions, reducing unnecessary echocardiography referrals by up to 66% while identifying high-priority patients who require specialist assessment. Cardio-HART functions as both a triage and diagnostic support tool, bridging the diagnostic gap between ECG screening and echocardiography, ultimately enabling earlier clinical decision-making before symptoms escalate.

Company description · Cardio-Phoenix official website